KELSO Pharma, the growing UK-based specialty pharma business, has concluded a deal to acquire two UK approved products, representing an exciting launch into the specialty of Dermatology with prescription medicines for the treatment of actinic keratoses and plaque psoriasis.
The two dermatology products, purchased from an organisation within the Dermapharm Group, represent another exciting move for Kelso Pharma as the business continues to grow, with collaborative partnerships, innovative medicines and top talent helping drive recent growth.
Kelso Pharma is focused on bringing innovative, value added, specialty medicines to the European healthcare markets, providing medicines that improve the lives of patients in a cost-effective and ethical manner. The company is growing through a blend of company and product acquisitions, partnerships and organic growth initially in the UK but seeking to expand its business into the rest of Europe.
Since its inception in 2020, Kelso Pharma has taken a number of positive steps to grow the business in an effective and sustainable manner, positively impacting patients and their families. The acquisition of Glasgow-based Stirling Anglian Pharmaceuticals (SAP) in January 2022 provided a new UK platform and a springboard for future sales growth for the business. SAP’s brand portfolio already includes four medicines in the UK healthcare market, including Acepiro® (acetylcysteine 600mg effervescent tablets) which was launched earlier this year and is used in the management of chronic obstructive airways disease.
Commenting on this announcement, Dr Tom Stratford, Chief Executive Officer at Kelso Pharma, said:
“This exciting acquisition signifies another important milestone, not just for our team at Kelso Pharma, but most importantly for patients. Launching into the specialty of Dermatology allows us to reach more patients across a number of regions as we continue to grow our business.
“Our team continues to work hard to create collaborative partnerships and identify further potential opportunities to expand our portfolio.”
